Landes Bioscience www.landesbioscience.com

Supplemental Material to:

Nathan J Schuld, Andrew D Hauser, Adam J Gastonguay, Jessica M Wilson, Ellen L Lorimer, and Carol L Williams

SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers

Cell Cycle 2014; 13(6)
http://dx.doi.org/10.4161/cc.27804

http://www.landesbioscience.com/journals/cc/article/27804



<u>Supplemental Figure 1:</u> Representative histogram plots for FACs cell cycle analysis. Experimental design is as described previously (**Fig. 3**).



<u>Supplemental Figure 2:</u> Protein expression blots in cancer cell lines after knockdown of SmgGDS splice variants. Experimental design is as described previously (**Fig. 4).**



<u>Supplemental Figure 3:</u> H1703-LUC-TR cell line stably expressing shRNA C2 representative blots. Experimental design is as described previously (**Fig. 5A).** The blots represent two additional, independent, replications of the data in Fig. 5A conducted on different dates. The lower blot utilizes 0, 1, and 5 μg of tetracycline as indicated in the figure.



<u>Supplemental Figure 4:</u> Additional mouse tumor data. A. The scatterplot represents raw starting luciferase value for each mouse used in the study injected with the indicated cell lines (+ or – doxycycline). Value is shown as Radiance (p/sec/cm^2/sr) and is reported as the number x10^6. There was

no significant difference between the doxycycline treated and non-doxycycline treated starting luciferase values for each injected cell line. **B.** The graphs represent relative weekly growth of tumors as described previously (**Fig. 5**) with the addition of week 7-10 data. The number of mice at week 7 in the control group (Sc #3) fell below the 6 mouse threshold for the study. The number of mice for each treatment group is indicated below the graph.